共 268 条
[1]
Zinman B(2015)Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 373 2117-2128
[2]
Wanner C(2017)Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes N Engl J Med 377 644-657
[3]
Lachin JM(2019)Dapagliflozin and cardiovascular outcomes in type 2 diabetes N Engl J Med 380 347-357
[4]
Fitchett D(2019)Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial Circulation 140 1463-1476
[5]
Bluhmki E(2019)Dapagliflozin in patients with heart failure and reduced ejection fraction N Engl J Med 381 1995-2008
[6]
Hantel S(2020)Cardiovascular and renal outcomes with empagliflozin in heart failure N Engl J Med 72 1845-1855
[7]
Neal B(2018)Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review J Am Coll Cardiol 6 435-437
[8]
Perkovic V(2018)SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection Lancet Diabetes Endocrinol 75 435-447
[9]
Mahaffey KW(2020)Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress Cardiovasc Res. 75 422-434
[10]
de Zeeuw D(2020)Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review J Am Coll Cardiol 18 129-511